MBX Biosciences' stock price plummeted 5.08% during intraday trading on Friday, as the company faces negative earnings expectations ahead of its upcoming financial report.

According to recent earnings preview data, MBX Biosciences is expected to report a loss of 58 cents per share for the period ending March 31, 2026, with the company anticipated to show no change in quarterly revenue when it reports results on May 11. While the mean earnings estimate has risen by about 10.9% in the last three months, the continued projected losses appear to have weighed on investor sentiment.

The stock's decline comes despite Wall Street's median 12-month price target of $63.00, representing approximately 125.4% upside from its previous closing price of $27.95, and an overall "buy" rating from analysts with 10 "strong buy" or "buy" recommendations versus just 1 "sell" or "strong sell" rating.